Objective: Controlled clinical trials in pediatric psychopharmacology rely on blinded parents and clinical evaluators for outcome data, but little is known about the success of the masking procedures. The blindness of clinical evaluators and parents was examined in a clinical trial of risperidone in autism. Methods: Clinical evaluators and parents were asked to guess individual treatment assignments at the end of an 8-week placebocontrolled trial of risperidone in children (aged 5-17 years) with autism. Clinical evaluators did not have access to adverse event data. Results: The rates of correctly guessing individual treatment assignment (risperidone or placebo) were significantly greater than chance for both clinical evaluators and parents (P < 0.001). Clinical evaluators associated improvement with attribution to risperidone, and lack of improvement with attribution to placebo, in both the risperidone and placebo treatment arms. Parents associated improvement with attribution to risperidone only in the placebo treatment arm. Parents reported that adverse events influenced their guesses, but presence of adverse events was not associated with correctness of guess. Conclusion: Improvement was associated with attribution to active treatment regardless of actual treatment assignment, and adverse events did not appear to be a threat to study blindness. (J Clin Psychopharmacol 2005;25:565-569) 
A critical feature of controlled clinical trials is masking of individual treatment assignment to research participants and evaluators of treatment outcomes (''doubleblind'' condition). 1 Assessment of the integrity of blindness is listed as an essential component of clinical trial reports in the Consolidated Standards of Reporting Trials, 2 but few studies are evaluated for level of blindness in either internal medicine or psychopharmacology. [3] [4] [5] Research on blindness integrity in pediatric psychopharmacology has been especially limited despite the recent increase in the number and size of controlled trials in children. 6, 7 Complete maintenance of blindness seems difficult to achieve regardless of trial design and procedures, 8, 9 The definition of integrity of study blindness itself remains the object of debate and interpretation. The standard approach to testing blindness integrity is to ask both investigators and subjects to guess treatment assignment at the end of treatment and to determine whether the accuracy of guessing individual treatment assignment was better than expected by chance alone. 3, 8, 10 Although a rate of correct guess better than expected by chance alone is often taken as evidence of unsuccessful masking, other considerations must be weighed. The relationship between attribution to active drug and improvement or adverse events (AEs) seems especially relevant to determining the integrity of study blindness. 5, 6 A link between improvement and treatment attribution by guessing clinicians and subjects was found in some adult and child studies, 4, 6, 7 although not in others. 5 Correct guesses occurred at a chance level in the absence of efficacy.
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Treatment attribution was apparently driven by the presence of AEs in some studies, 5, 7, 12, 13 but not in others. 4 This variability across studies can be due to differences in type of drugs, subjects, experimental design, and methods. Thus, random assignment to drugs with specific and evident AEs, such as b-blockers, benzodiazepines, tricyclic antidepressants, or neuroleptics, is expected to be more easily recognized than in the case of drugs with a less distinctive tolerability profile, such as the selective serotonin reuptake inhibitors.
The aim of this analysis was to assess the integrity of the blindness condition of a placebo-controlled trial of risperidone in children with autism and severe behavioral problems.
14 In this study, each child was assigned to a treating clinician, who collected AE data and adjusted drug dose at each weekly visit, and a clinical evaluator, who assessed efficacy. Guesses of treatment attribution were independently obtained from evaluator and parent at the end of each child's treatment. It was hypothesized that treatment attribution would be associated with improvement (ie, improved patients would be attributed to having received active drug and unimproved to having received placebo) in both the active and the placebo arms. It was also hypothesized that AEs would influence the parents' guess, but not the clinical evaluators' guess. Parents, who knew of AEs, were expected to be correct more often than clinical evaluators, who did not have access to AE data.
METHODS

Description of the Clinical Trial
This was a multisite, 8-week, double-blind, placebocontrolled trial of risperidone in 101 children (aged 5-17 years) with autism accompanied by severe tantrums, aggression, and/or self-injurious behavior. 15 Children were randomized on a 1:1 ratio to either risperidone (mean dose, 1.8 ± 0.7 mg/d; range, 0.5-3.5 mg/d) or matched placebo. Randomization was centralized and balanced, within site, for sex, Tanner stage, and use of anticonvulsant medication, with sequential treatment assignment. 15 Primary outcome measures were the Irritability subscale of the Aberrant Behavior Checklist, completed by the parent, and the Clinical Global Impression-Improvement Scale, completed by the clinical evaluator. Three children on risperidone (due to lack of efficacy) and 18 children on placebo (12 for lack of efficacy, 1 for AE, and 5 for other reasons) prematurely terminated the trial. Based on intent-to-treat analyses, risperidone was better than placebo at decreasing behavioral symptoms (P < 0.001). The rate of response (defined by a score of ''much improved'' or ''very much improved'' on the Clinical Global Impression-Improvement Scale and a decrease of at least 25% on the Irritability subscale of the Aberrant Behavior Checklist score) was 69% in the risperidone and 12% in the placebo group (P < 0.001). Based only on Clinical Global Impression-Improvement Scale scores, the rate of response was 75.5% in the risperidone group and 11.5% in the placebo group (P < 0.001). In the risperidone group (n = 49), 16 children (33%) had no AEs and 33 (67%) had 1 or more AEs. In the placebo group (n = 52), 34 (71%) subjects had no AE, and 18 (37%) had at least 1 AE. Increased appetite, weight gain, tiredness, drowsiness, drooling, constipation, dizziness, tremor, and tachycardia were more common with risperidone (P < 0.10). 14 
Blindness Procedures
Risperidone and placebo were supplied by Janssen Pharmaceutica as tablets identical in appearance, and packaged centrally. Clinical evaluators were not involved in assessing AEs or adjusting the medication dosage (a separate clinician was in charge of the treatment) and remained blind to individual treatment assignment for the entire duration of the trial (22 months). However, complete independence of evaluators and parents in scoring improvement was not possible, because evaluators derived information from interviewing the parents, who knew about AEs, and from direct patient observation, which can be revealing of AEs.
Guess of Treatment Assignment by Clinicians and Parents
Evaluators and parents were asked to guess independently which arm (risperidone or placebo) they believed the child had been assigned as part of the end-of-treatment assessments. If they were completely uncertain and unwilling to guess, they could select a ''completely uncertain'' category. The children could not be surveyed because of their cognitive impairment. Evaluators and parents were also asked to indicate the reason(s) for their guess among ''presence of efficacy,'' ''absence of efficacy,'' ''presence of AEs,'' ''absence of AEs,'' and ''other.'' Overall, blindness assessments were completed for 96% of the study participants.
Statistical Analyses
Presence of correct guess above chance level was tested with the binomial test, across all subjects and by treatment group. The degree of correct guess above chance level was estimated using the formula p rk = (n 1 À n 2 )/ n 1 + n 2 + n 3 , where n 1 is the number of correct guesses, n 2 the number of incorrect guess, and n 3 the number of cases without a guess because of complete uncertainty. 10 This index uses all the available information to estimate the proportion of correct guesses above chance level, with a p rk = 0 indicating a guess at chance level (ie, 50% of time correct for a 1:1 randomization) and p rk = 1 indicating perfect guessing. Association between treatment attribution and improvement status or presence of AEs was examined using odds ratios. Statistical significance, set at 2-tailed P 0.05, was tested with x 2 or Fisher exact test, as appropriate. Improvement status was defined categorically as responder or nonresponder, based on the trial prespecified criteria. Subjects with at least 1 documented AE during the trial were counted in the AE group.
RESULTS
Rates of Correct Guess
Clinical evaluators and parents guessed correctly individual treatment assignment better than expected by chance *Clinical evaluator attribution was correct in 78%, incorrect in 11%, and completely uncertain in 10% of the cases; parent attribution was correct in 84%, incorrect in 10%, and completely uncertain in 5% of cases, with no statistically significant differences between clinician and parent rates by x 2 test. When a guess was made, it was correct in 87.4% of cases among clinicians and 89.1% among parents. These rates were greater than expected by chance (binomial test, P < 0.001).
only (Table 1) . Clinicians guessed correctly 87.4% of the time, and parents guessed correctly 89.1% of the time (P < 0.001, binomial test). Among clinical evaluators, the proportion of guesses above the chance level ( p rk ) was 0.67 (95% confidence interval [CI], 0.62-0.72) across both treatment groups, 0.73 (95% CI, 0.68-0.78) in the risperidone group, and 0.60 (95% CI, 0.52-0.68) in the placebo group. Among parents, the proportion of guesses above the chance level ( p rk ) was 0.74 (95% CI, 0.69-0.79) across both treatment groups, 0.89 (95% CI, 0.85-0.93) in the risperidone group, and 0.59 (95% CI, 0.51-0.67) in the placebo group.
Rates of correct guesses and reported level of uncertainty did not significantly differ between clinical evaluators and parents (Table 1) . Overall degree of agreement between clinical evaluators and parents was very high (k coefficient = 0.90), with concordance on treatment attribution in 78 (81%) of the cases.
Because the entire trial took 22 months to complete, the effect of time on rate of correct guess was estimated. The sample was stratified into 3 subgroups using sequential order of randomization: early (n = 32), middle (n = 33), and late (n = 32). The rate of correct guess did not vary over time (for clinician, x 2 = 0.16, P = 0.93, for risperidone and x 2 = 1.65, P = 0.44, for placebo; for parent, x 2 = 0.0, P = 1.0, for risperidone and x 2 = 2.28, P = 0.32, for placebo).
Improvement, Adverse Events, and Treatment Attribution
Among clinical evaluators, responder status was linked to attribution to risperidone in both the risperidone and the placebo arms (Table 2 ). In the risperidone group, 31 (91%) of the 34 responders were attributed to risperidone, and in the placebo group, 5 (83%) of the 6 responders were also attributed to risperidone. Among parents, the link between response and attribution to risperidone was statistically significant only in the placebo arm. In the risperidone arm, parents were more likely to attribute nonresponders to risperidone correctly (n = 12 of 14, binomial test, P = 0.05). Of these 12 subjects, only 9 had AEs. Presence of AEs was not associated with the direction of the attribution by either clinical evaluators or parents (Table 3 ). Clinicians listed presence or absence of improvement as clue for their guess for 98% of the subjects in the placebo arm and 100% of the subjects in the placebo arm. Parents listed presence of absence of improvement as clue for their guess for 89% of the subjects in the placebo arm and for 98% of the subjects in the risperidone arm. Parents also listed presence of AEs as a clue for 13% of the placebo and for 29% of the risperidone subjects, and absence of AEs as a clue for 53% of the placebo and 27% of the risperidone subjects.
DISCUSSION
In this placebo-controlled trial of risperidone in children, clinical evaluators correctly guessed individual treatment assignment in 78% of the cases and parents in 84% of the cases. These rates are much greater than expected by chance. Improvement, but not presence of AEs, was associated with attribution to active treatment (Tables 2 and 3) . Among clinical evaluators, improvement was associated with attribution to active medication and absence of improvement with attribution to placebo, regardless of which treatment arm the subject had actually been assigned. Among parents, however, the effect of improvement was statistically significant only in the placebo group.
Despite the strong link between improvement and guessing active treatment, other factors seem to influence clinician's attribution, as suggested by the fact that approximately 50% of the patients who did not respond to risperidone were attributed to risperidone, as compared with only 7% of those who did not respond to placebo (Table 3) . It is possible that subthreshold levels of improvement that did not qualify the patient for responder status might have influenced guessing, as well as some obvious AEs, such as weight gain, detected while observing the patient.
Because guess was assessed at the end of treatment and not prospectively during the trial, the chronological relationship between improvement and treatment attribution cannot be elucidated. Although it is theoretically possible that a belief of being assigned to active or inactive treatment led to improvement, and not vice versa, this hypothesis does not seem plausible especially in a study of severely impaired autistic children, usually unresponsive to placebo. The obvious explanation for the observed association between improvement and attribution to risperidone is that it resulted from an expectation of benefit from the drug. It was, however, a limitation that investigator and parent expectations were not assessed. In future trials, the inclusion of measures of clinician and participant expectation at study entry can help interpret end-of-study treatment attribution. Another limitation of the study is that only the guesses from clinical evaluators and parents were collected, but not from the treating clinicians in charge of AE assessment and medication dose adjustments.
It is noteworthy that the parents, who were inevitably aware of the child's AEs, were not more likely to be correct in their guesses than the clinical evaluators (Table 1) . Even if parents listed AEs as a clue for their guess, presence of AEs was not associated with the direction of the guess (Table 2 ). This finding is remarkable when considering that risperidone was associated with significantly more AEs than placebo. Thus, in the context of clear-cut superiority of active medication over placebo, the threat to blindness from AEs appears to be negligible.
These results indicate that the evaluation of blindness integrity in clinical trials is complex and cannot rely on testing merely whether the rate of correct guess was above chance level. We propose that, to meet the Consolidated Standards of Reporting Trials requirement to include an evaluation of study blindness in reporting clinical trials, a systematic evaluation be conducted to determine whether the expected bias to associate improvement or AEs to active treatment applied to both the active and placebo arms. A double-blind clinical trial may be considered unbiased even with a highly accurate rate of correct guess, if it can be shown that attribution to active drug or placebo was associated with improvement status regardless of actual treatment assignment.
